A Phase III Open Label Extension Study of CM-AT in Children With Autism
Phase of Trial: Phase III
Latest Information Update: 03 Mar 2019
Price : $35 *
At a glance
- Drugs CM 4612 (Primary)
- Indications Autistic disorder
- Focus Therapeutic Use
- Acronyms CM-AT
- Sponsors Curemark
- 07 Mar 2017 Status changed from active, no longer recruiting to completed.
- 19 Apr 2016 Planned End Date changed from 1 May 2016 to 1 Aug 2016.
- 19 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Aug 2016.